UNSPSC 51171952: Nolinium

This classification denotes an antiulcerative with the molecular formula C15H11Cl2N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N018S592LP, chemically known as 2-(3,4-dichloroanilino)quinolizinium but generally known as nolinium, which bears US NIH Compound Identifier 38666. The term NOLINIUM is an International Non-Proprietary Name or INN. European Medicines Agency schedules nolinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09343MIG.

As of Q4 2014, NOLINIUM remains the US FDA Preferred Term for this commodity. SMILES: C1=CC=[N+]2C=CC(=CC2=C1)NC3=CC(=C(C=C3)Cl)Cl.

UNSPSC 51171952 Nolinium, a Commodity code, comprises laboratory chemical reagents and supplies used in clinical drug testing and pharmaceutical manufacturing quality assurance — specifically immunoassay screening materials, confirmatory testing reagents (LC/MS/MS and GC/MS), and ancillary testing consumables for offender drug screening and compliance monitoring. State and local governments procure these materials primarily through county community supervision and corrections departments and state health and human services agencies managing drug testing programs, pharmaceutical benefit operations, and multi-jurisdictional cooperative purchasing initiatives that distribute generics and OTC products across public health systems.

Collin County Community Supervision and Corrections Department (Texas) posted RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, renewable for up to three additional one-year periods. The scope encompasses immunoassay screening with LC/MS/MS or GC/MS confirmation across approximately 25,031 annual tests, with staffing of two collection sites in Plano and McKinney, operation of an Interactive Voice Response notification system, and alternative testing methodologies including oral fluid and hair analysis. At the state level, the Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models and value-based agreements outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendor compliance with cGMP, DSCSA certification, and relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and pricing format flexibility. Recent activity spans Texas counties and multi-state cooperative purchasing arrangements with secondary participation from Oregon.